Skip to content Outputs by Type Journal article
2020
Late changes in blood-brain barrier permeability in a rat tMCAO model of stroke detected by gadolinium-enhanced MRI Morgan, C.A., Mesquita, M., Ashioti, M., Beech, J.S., Williams, S.C.R., Irving, E. and Cash, D. 2020. Late changes in blood-brain barrier permeability in a rat tMCAO model of stroke detected by gadolinium-enhanced MRI. Neurological Research. 42 (10), pp. 844-852. https://doi.org/10.1080/01616412.2020.1786637 Article
2013
Immunolocalization of kisspeptin associated with amyloid-β deposits in the pons of an Alzheimer’s disease patient Chilumuri, A., Ashioti, M., Nercessian, A.N. and Milton, N.G.N. 2013. Immunolocalization of kisspeptin associated with amyloid-β deposits in the pons of an Alzheimer’s disease patient. Journal of Neurodegenerative Diseases. 2013 879710. https://doi.org/10.1155/2013/879710
2013
Sulforaphane alters cerebral leukocyte endothelial cell interactions post global ischaemia reperfusion Gillespie, S., Milton, N.G.N., Ashioti, M. and Gavins, F.N.E. 2013. Sulforaphane alters cerebral leukocyte endothelial cell interactions post global ischaemia reperfusion. FASEB Journal. 27, p. 687.18.
2012
Kisspeptin prevention of Amyloid-β Peptide neurotoxicity in vitro Milton, N.G.N., Chilumuri, A., Rocha-Ferreira, E., Nercessian, A.N. and Ashioti, M. 2012. Kisspeptin prevention of Amyloid-β Peptide neurotoxicity in vitro. ACS chemical neuroscience. 3 (9), pp. 706-719. https://doi.org/10.1021/cn300045d
2009
Neither in vivo MRI nor behavioural assessment indicate
therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke Ashioti, M., Beech, J.S., Lowe, A.S., Bernanos, M., McCreary, A., Modo, M.M. and Williams, S.C.R. 2009. Neither in vivo MRI nor behavioural assessment indicate
therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke. BMC Neuroscience. 10 (82). https://doi.org/10.1186/1471-2202-10-82
